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› Intensify diabetes 
treatment for patients who 
have a normal fasting 
glucose, but an HbA1c >7% 
and daytime hyperglycemia, 
and for those who are not 
at goal despite basal insulin 
doses >0.5 units/kg/d.  B
› Consider intensifying 
diabetes management 
beyond basal insulin therapy 
by adding a glucagon-like 
peptide 1 receptor agonist,  
insulin prior to one meal 
each day, or insulin 
prior to all meals.  C
Strength of recommendation (SOr)
  Good-quality patient-oriented 
evidence
  Inconsistent or limited-quality 
patient-oriented evidence
  Consensus, usual practice,  
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Diabetes mellitus is a complex, progressive disease that affects every family physician’s practice. Major diabetes organizations recommend that treatment be ongoing 
and progressive in order to control the disease. The American 
Diabetes Association (ADA), the European Association for the 
Study of Diabetes (EASD), and the American Association of 
Clinical Endocrinologists recommend that patients be assessed 
every 2 to 3 months after diagnosis and that treatment should be 
intensified if the patient is not meeting treatment goals.1,2 Using 
this approach, all people with type 2 diabetes could be on insu-
lin one year after diagnosis.1,2 
While many family physicians have become comfort-
able with using once-daily basal insulin such as glargine or 
detemir, what to do after basal insulin is much more complex. 
This review builds upon an earlier article in this journal, “In-
sulin for type 2 diabetes: How and when to get started,”3  by 
explaining 3 strategies to consider when basal insulin alone 
isn't enough. 
3 main strategies  
for intensifying treatment
Basal insulin is indicated for patients who have glucose 
toxicity and persistently elevated hemoglobin A1c (HbA1c) 
despite using 2 or more oral agents, or for those who have 
not achieved glucose goals one year into treatment.3,4 ADA/
EASD recommends initiating a weight-based approach for 
basal insulin therapy based on initial HbA1c levels >7% or 
>8%.4 Instructing and encouraging patients to titrate their 
own insulin dose based on fasting glucose readings provides 
greater and faster glucose control.1,2 
Despite these attempts, some patients will not reach their 
glucose goals with basal insulin. When intensifying treatment 
beyond basal insulin therapy, patient preference, cost-effec-
tiveness, safety, tolerability, glycemic efficacy, risk of hypogly-
What to do after basal insulin:  
3 Tx strategies for type 2 diabetes
These strategies can help you optimize glucose control 
in your patient with type 2 diabetes when basal insulin 
alone isn’t sufficient.
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cemia, effects on cardiovascular risk factors, 
and other non-glycemic effects should be 
considered in the shared decision-making 
process. There are 3 main strategies for inten-
sifying treatment: 
1.  Basal plus incretin therapy. Add 
a newer injectable agent such as a 
glucagon-like peptide 1 receptor ago-
nist (GLP-1RA).
2.  Basal plus one strategy. Add prandial in-
sulin prior to the largest meal of the day. 
 3.  Basal-bolus combination. Add insu-
lin prior to all meals.
tABLe 15-8 provides details of several 
studies that have documented the efficacy of 
these 3 strategies.
Monitoring blood glucose 
to guide the way
Blood glucose monitoring using 
either a 7-point glucose moni-
toring technique or stag-
gered glucose checks 









a day and 
an additional 
bedtime read-
ing.9 This is typi-
cally performed for 
3 to 7 days prior to 
an appointment and 
provides an estimate of 
a typical full day’s glucose 
pattern. 
Staggered monitoring in-
cludes a pair of glucose checks tak-
en immediately before and typically 
90 minutes after a meal. This is assigned 
to a different meal each day in order to ob-
tain the same information as is achieved with 
7-point monitoring, but with fewer checks on 
any given day. It may take up to 2 to 3 weeks 
to gather the necessary information using the 
staggered monitoring technique. 
In order to optimize insulin strategies 
for tighter glycemic control, it is important to 
review blood glucose logs at each office visit 
with either of the above techniques. 
Basal plus incretin therapy
GLP-1RAs are subcutaneously administered 
injectable incretin agents. They mimic the 
action of endogenous GLP-1 hormones, 
which are normally secreted in re-
sponse to meals 







release from pancreatic al-
pha cells, signals satiety, and 
slows gastric emptying.10 In 
other words, GLP-1 appears to be 
a physiologic regulator of appetite 
and food intake. GLP-1 is rapidly me-
tabolized and inactivated by dipeptidyl 
peptidase-4 (DPP-4) enzymes.10 The amplifi-
cation of insulin secretion elicited by hormones 
secreted from the gastrointestinal (GI) tract is 
called the “incretin effect.”10 Obesity, insulin re-
sistance, and type 2 diabetes greatly reduce the 
incretin effect.10
GLP-1RAs mimic the incretin effect and 
are not degraded by endogenous DPP-4 en-
zymes.10 They provide a pharmacologic level 
of GLP-1 activity, including beneficial glu-
cose effects (via insulin secretion and gluca-
gon suppression), but they also increase GI 
adverse effects, such as nausea and vomit-
ing.11-15 Further, they can suppress appetite 
and contribute to weight loss.11-15
GLP-1RAs can be considered as an add-
on therapy for patients whose HbA1c ex-
ceeds 7% and whose fasting blood glucose 
ranges from 80 to 130 mg/dL, or for patients 
with a basal insulin dose >0.5 unit/kg/d. The 













should be  
guided by  
glucose  
monitoring  
using the 7-point 
technique  
or staggered  
glucose checks.
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tABLe 1
3 ways to intensify type 2 diabetes treatment: A look at the evidence
Study (date) Patients (n) Treatment groups Trial duration hba1c fasting plasma glucose conclusions
Basal plus GlP-1ra 





1.  albiglutide, 30 mg 
weekly titrated to 50 mg 
if necessary, plus once-
daily titrated glargine
2.  Titrated preprandial 
insulin lispro 3 times/d 
plus once-daily titrated 
glargine





by 0.82% with 
albiglutide, 0.66% 
with insulin lispro. 
Treatment  




Similar at baseline (data not 
published). mean was lower in 
albiglutide group (P=.236)
after 26 weeks, hba1c reduction, goal hba1c 
<7%, and goal hba1c <6.5% was comparable and 
noninferior in both treatment groups. Weight was 
significantly lower in the albiglutide group. adverse 
reactions were comparable. findings supports  
noninferiority between albiglutide and insulin lispro 
and a weight-loss benefit with albiglutide
Basal plus one 





1.  Glargine daily with oha 
(control group)
2.  addition of glulisine 
to the main meal with 













0.37±0.09% in  
glulisine group 
(P=.029)
overall baseline: 143±40 mg/dl. 
Decreased to 110±22 mg/dl 
(control group) vs 111±22 mg/
dl (glulisine group)
hba1c <7% at 6 months was reached more  
frequently by participants in the glulisine group 
than those in the control group. findings support 
the rationale, safety, and efficacy of adding a single 
dose of glulisine to ongoing glargine plus ohas to 
improve hba1c and mean daily plasma BG when 
hba1c targets have not been met





1.  addition of glulisine at 
breakfast to existing 
glargine regimen
2.  addition of glulisine  
at main mealtime  
to existing glargine  
regimen
24 weeks overall baseline: 
7.3±0.7%.  
Decreased by 0.5% 
in breakfast  
glulisine group, 
0.6% in main  
mealtime glulisine 
group (P<.001)
overall baseline increased 
from 6.0±0.8 mmol/l (108±14 
mg/dl) to 6.7±1.4 mmol/l 
(121±25 mg/dl) in breakfast 
group, and from 5.9±0.8 
mmol/l (106±14 mg/dl) to 
6.3±1.4 mmol/l (113±25 mg/dl) 
in main mealtime group
Glulisine given at breakfast was equally effective 
in controlling hba1c as glulisine given at the main 
mealtime. Significantly more patients achieved 
target hba1c ≤7% in the main mealtime group. 
changes in weight (nS) and rates of hypoglycemia 
(nS) were comparable in both groups
Basal-bolus combination





1.  one insulin glulisine 
injection with the  
largest meal of the day 
(1X group)
2.  one glulisine injection 
prior to 2 meals/d  
(2X group)
3.  one glulisine injection 
prior to 3 meals/d  
(3X group)
24 weeks overall baseline: 
7.8%. Decreased by 
0.44% in 1X group, 
0.36% in 2X group, 
0.43% in 3X group 
(nS)
overall baseline:  
131 mg/dl. Data (not  
published) was reported  
as comparable in all groups  
at the end of study
at 24 weeks, hba1c reductions was noninferior 
among 1X or 2X groups compared to 3X group. 
however, a greater number of patients achieved 
hba1c <7% in the 3X group (46%) vs the  
1X (34%) and 2X (30%) groups (P=.17 and P=.045, 
respectively). findings confirm that a regimen with 
multiple daily injections is more likely to reach  
target hba1c levels without a significant impact  
on weight or hypoglycemia
BG, blood glucose; Dm, diabetes mellitus; hba1c, hemoglobin a1c; nS, not significant; oha, oral hypoglycemic agent.
exenatide extended-release, liraglutide, al-
biglutide, and dulaglutide) are compared in 
tABLe 2.11-15
Dosing varies with each agent and in-
cludes twice daily before meals for exena-
tide, once daily (independent of meals) for 
liraglutide, and once weekly for exenatide ex-
tended-release, albiglutide, and dulaglutide. 
These agents should not be used for patients 
with a history of pancreatitis or a personal or 
family history of medullary thyroid cancer or 
multiple endocrine neoplasia type 2. Because 
exenatide is cleared through the kidneys, its 
use is contraindicated in patients with a cre-
atinine clearance <30 mL/min or end-stage 
renal disease. Caution is advised for its use in 
patients with a creatinine clearance of 30 to 
50 mL/min.11
WHAT TO DO AFTER BASAL INSULIN
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glucose-monitoring burden for the patient, it 
may be acceptable to allow the patient to omit 
the fasting glucose measurement (if stable). 
The first major decision is whether to 
treat one meal per day (basal plus one) or all 
meals (basal-bolus). Adding a rapid-acting 
insulin prior to one meal a day (usually the 
largest meal) is a reasonable starting point.16 
The meal that produces the highest post-
prandial glucose readings can be considered 
the meal of greatest glycemic impact. The 
“delta” value—the difference between pre-
meal glucose and 2-hour postprandial glu-
cose readings—also helps to determine the 
largest meal of the day.17 The average physi-
ologic delta is ≤50 mg/dL.17 If the delta for a 
meal is >75 mg/dL, consider initiating pran-
dial insulin prior to that meal and titrating 
the dose to achieve a target glucose level of 
<130 mg/dL before the next meal.
Using 4 to 6 units of a rapid-acting in-
sulin per meal is a good initial regimen for a 
basal plus one (as well as for a basal-bolus) 
approach.16 If the patient experiences signifi-
cantly increased insulin demands as indicat-
ed by glucose patterns where the post-meal 
glucose is still consistently above 180 mg/dL, 
the initial regimen may be modified to 
0.1 unit per kg per meal,17-19 and then titrated up 
to a maximum of 50% of the total daily insulin 
dose (TDD) for basal plus one16 (or 10%-20% of 
TDD per meal for basal-bolus).
z Consider the timing of administra-
tion. Rapid-acting insulin analogs exhibit 
peak pharmacodynamic activity 60 minutes 
after injection (tABLe 3).20 
Peak carbohydrate absorption following 
a meal occurs approximately 75 to 90 minutes 
after eating begins.17,21 Thus, to synchronize 
the action of insulin with carbohydrate diges-
tion, the analog should be injected 15 min-
utes before meals. This can be increased by 
titrating prandial insulin by 1 unit/d to a goal 
of either a 90-minute to 2-hour postprandial 
glucose of <140 to 180 mg/dL or the next pre-
prandial glucose of <130 mg/dL.16 The goal 
is to obtain a near-normal physiologic delta 
of <50 mg/dL. The drop in delta noted with 
every unit of insulin added to the current 
dose can provide a rough approximation of 
how many additional insulin titrations will be 
needed to achieve a delta of <50 mg/dL.
A GLP-1rA can 
be considered 
for patients with 
an HbA1c >7% 
and a fasting 
glucose ranging 
from 80 to  
130 mg/dL.
Study (date) Patients (n) Treatment groups Trial duration hba1c fasting plasma glucose conclusions
Basal plus GlP-1ra 





1.  albiglutide, 30 mg 
weekly titrated to 50 mg 
if necessary, plus once-
daily titrated glargine
2.  Titrated preprandial 
insulin lispro 3 times/d 
plus once-daily titrated 
glargine





by 0.82% with 
albiglutide, 0.66% 
with insulin lispro. 
Treatment  




Similar at baseline (data not 
published). mean was lower in 
albiglutide group (P=.236)
after 26 weeks, hba1c reduction, goal hba1c 
<7%, and goal hba1c <6.5% was comparable and 
noninferior in both treatment groups. Weight was 
significantly lower in the albiglutide group. adverse 
reactions were comparable. findings supports  
noninferiority between albiglutide and insulin lispro 
and a weight-loss benefit with albiglutide
Basal plus one 





1.  Glargine daily with oha 
(control group)
2.  addition of glulisine 
to the main meal with 













0.37±0.09% in  
glulisine group 
(P=.029)
overall baseline: 143±40 mg/dl. 
Decreased to 110±22 mg/dl 
(control group) vs 111±22 mg/
dl (glulisine group)
hba1c <7% at 6 months was reached more  
frequently by participants in the glulisine group 
than those in the control group. findings support 
the rationale, safety, and efficacy of adding a single 
dose of glulisine to ongoing glargine plus ohas to 
improve hba1c and mean daily plasma BG when 
hba1c targets have not been met





1.  addition of glulisine at 
breakfast to existing 
glargine regimen
2.  addition of glulisine  
at main mealtime  
to existing glargine  
regimen
24 weeks overall baseline: 
7.3±0.7%.  
Decreased by 0.5% 
in breakfast  
glulisine group, 
0.6% in main  
mealtime glulisine 
group (P<.001)
overall baseline increased 
from 6.0±0.8 mmol/l (108±14 
mg/dl) to 6.7±1.4 mmol/l 
(121±25 mg/dl) in breakfast 
group, and from 5.9±0.8 
mmol/l (106±14 mg/dl) to 
6.3±1.4 mmol/l (113±25 mg/dl) 
in main mealtime group
Glulisine given at breakfast was equally effective 
in controlling hba1c as glulisine given at the main 
mealtime. Significantly more patients achieved 
target hba1c ≤7% in the main mealtime group. 
changes in weight (nS) and rates of hypoglycemia 
(nS) were comparable in both groups
Basal-bolus combination





1.  one insulin glulisine 
injection with the  
largest meal of the day 
(1X group)
2.  one glulisine injection 
prior to 2 meals/d  
(2X group)
3.  one glulisine injection 
prior to 3 meals/d  
(3X group)
24 weeks overall baseline: 
7.8%. Decreased by 
0.44% in 1X group, 
0.36% in 2X group, 
0.43% in 3X group 
(nS)
overall baseline:  
131 mg/dl. Data (not  
published) was reported  
as comparable in all groups  
at the end of study
at 24 weeks, hba1c reductions was noninferior 
among 1X or 2X groups compared to 3X group. 
however, a greater number of patients achieved 
hba1c <7% in the 3X group (46%) vs the  
1X (34%) and 2X (30%) groups (P=.17 and P=.045, 
respectively). findings confirm that a regimen with 
multiple daily injections is more likely to reach  
target hba1c levels without a significant impact  
on weight or hypoglycemia
BG, blood glucose; Dm, diabetes mellitus; hba1c, hemoglobin a1c; nS, not significant; oha, oral hypoglycemic agent.
Basal plus one strategy
To best utilize prandial insulin, it is important 
to know what the patient’s glucose readings 
are before and after meals as assessed by the 
7-point or staggered blood glucose monitor-
ing techniques described earlier. Once you 
have clarified which meal(s) are raising the 
patient’s glucose levels, selecting appropri-
ate treatment becomes easier. To reduce the 
conTinueD
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Basal-bolus combination 
A gradual increase from one injection before 
a single meal each day to as-needed multiple 
daily injections (MDIs) is the next step in hy-
perglycemia management. Starting slow and 
building up to insulin therapy prior to each 
meal offers structure, simplicity, and physi-
cian-patient confidence in diabetes manage-
ment. The slow progression from basal plus 
one to basal-bolus combination allows the 
patient ease into a complex, labor-intensive 
regimen of MDIs. Additionally, the stepwise 
reduction of postprandial hyperglycemia with 
this slow approach often reduces the incidence 
of hypoglycemia (more on this in a moment).8
Advanced insulin users can calculate an 
“insulin-to-carbohydrate ratio” (ICR) to esti-
mate the amount of insulin they need to ac-
commodate the amount of carbohydrates they 
ingest per meal. An ICR of 1:10 implies that the 
patient administers 1 unit of insulin for every 
10 grams of carbohydrates ingested. For exam-
ple, if a patient with an ICR of 1:10 concludes 
that his meal contains a total of 60 grams of car-
bohydrates, then he would administer 6 units 
of insulin prior to this meal to address the an-
ticipated post-meal hyperglycemia. 
In order to use the ICR regimen, a pa-
tient would need to be able to accurately de-
termine the nutritional content of his meals 
(starch, protein, carbohydrates, and fat) and 
calculate the appropriate insulin dosage. For 
successful diabetes management, it is es-
sential to evaluate the patient’s skills in these 
areas before starting an ICR regimen, and to 
routinely assess hypoglycemic episodes at 
follow-up visits. 
An ICR approach is usually reserved for 
patients who require tighter glucose control 
than that obtained from fixed prandial insu-
lin doses, such as patients with type 1 diabe-
tes, those with variable meal schedules and 
content, those with a malabsorption syn-
drome that requires consuming meals with a 
specific amount of carbohydrates, athletes on 
a structured diet with specific carbohydrate 
content, and patients who want flexibility 
with carbohydrate intake with meals. 
z the risk of hypoglycemia is a major 
barrier to initiating basal-bolus insulin ther-
apy. Hypoglycemia is classified as a blood 
glucose level of <70 mg/dL, and severe hypo-
glycemia as <50 mg/dL, regardless of whether 
the patient develops symptoms.22 Symptoms 
of hypoglycemia include dizziness, difficulty 
speaking, anxiety, confusion, and lethargy. 
Hypoglycemia can result in loss of conscious-
ness or even death.22 
A patient who has frequent hypoglycemic 
episodes may lose the protective physiologic 
response and may not recognize that he is 
experiencing a hypoglycemic episode (“hypo-
tABLe 2
GLP-1 receptor agonists used to treat type 2 diabetes*
medication Dosing frequency renal dosing relation to meals Warnings/precautions*
exenatide11 Twice daily  
(5 mcg, 10 mcg)
caution for cr clr  
of 30-50 ml/min
30-60 minutes before 
am and pm meals
Pancreatitis; thyroid c-cell 




once weekly  
(2 mg)
caution for cr clr  
of 30-50 ml/min
not related to meals Pancreatitis; thyroid  
c-cell cancer; avoid use with 
cr clr <30 ml/min or eSrD
liraglutide13 once daily  
(0.6 mg, 1.2 mg, 1.8 mg)
caution for cr clr  
of 30-50 ml/min
not related to meals Pancreatitis; thyroid  
c-cell cancer; men type 2
albiglutide14 once weekly 
(30 mg, 50 mg)
no dosage adjustment not related to meals medullary thyroid 
cancer
Dulaglutide15 once weekly 
(0.75 mg, 1.5 mg)
no dosage adjustment not related to meals Thyroid c-cell tumors. not 
studied with pancreatitis
cr clr, creatinine clearance; eSrD, end-stage renal disease; GlP-1, glucagon-like peptide 1; men, multiple endocrine neoplasia.
*  nausea is a common adverse effect of all GlP-1 receptor agonists; for some of these agents, weight loss and vomiting also are common. all GlP-1 receptor  
agonists are pregnancy category c. 
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WHAT TO DO AFTER BASAL INSULIN
Adding a rapid-
acting insulin 
prior to one 





glycemia unawareness”). This is why it is cru-
cial to ask patients if they have had symptoms 
of hypoglycemia, and to correlate the timing of 
these symptoms with blood glucose logs. For 
example, it is possible for a patient to experi-
ence hypoglycemic symptoms for blood glu-
cose readings in the 100 to 200 mg/dL range 
if his or her average blood glucose has been in 
the 250 to 300 mg/dL range. Such patient may 
not realize he is experiencing hypoglycemia 
until he develops severe symptoms, such as 
loss of consciousness. 
Hypoglycemia unawareness must be ad-
dressed immediately by reducing insulin dos-
ing to prevent all hypoglycemic episodes for 
2 to 3 weeks. This has been shown to “reset” 
the normal physiologic response to hypo-
references
medication Dosing frequency renal dosing relation to meals Warnings/precautions*
exenatide11 Twice daily  
(5 mcg, 10 mcg)
caution for cr clr  
of 30-50 ml/min
30-60 minutes before 
am and pm meals
Pancreatitis; thyroid c-cell 




once weekly  
(2 mg)
caution for cr clr  
of 30-50 ml/min
not related to meals Pancreatitis; thyroid  
c-cell cancer; avoid use with 
cr clr <30 ml/min or eSrD
liraglutide13 once daily  
(0.6 mg, 1.2 mg, 1.8 mg)
caution for cr clr  
of 30-50 ml/min
not related to meals Pancreatitis; thyroid  
c-cell cancer; men type 2
albiglutide14 once weekly 
(30 mg, 50 mg)
no dosage adjustment not related to meals medullary thyroid 
cancer
Dulaglutide15 once weekly 
(0.75 mg, 1.5 mg)
no dosage adjustment not related to meals Thyroid c-cell tumors. not 
studied with pancreatitis
tABLe 3
Time-action profiles for short-acting  
and rapid-acting insulin analogues20
insulin type onset (h) Peak (h) Duration (h)
regular (short-acting) 0.5 2-4 6-8
aspart (rapid-acting) ≤0.25 1-3 3-5
lispro (rapid-acting) ≤0.25 1 2-4 
Glulisine (rapid-acting) ≤0.25 1 3.5-4.5
glycemia, regardless of how long the patient 
has had diabetes.23,24 Even if your patient is 
aware of the warning signs of a hypoglycemic 
episode, it is important to routinely ask about 
hypoglycemia at all diabetes visits because pa-
tients may reduce insulin doses, skip doses, or 
eat defensively to prevent hypoglycemia. 
Other than the risk of hypoglycemia, in-
sulin typically has fewer adverse effects than 
oral medications used to treat diabetes. Most 
common concerns include weight gain, hy-
poglycemia, injection site reactions and, 
rarely, allergy to insulin or its vehicle.16              JFP
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